PAC0016PR: Pancreatic Moderately Differentiated Ductal Adenocarcinoma

TRACE-PDTX platform


Patient
Sex Female
Age at Time of Collection 46
Race / Ethnicity / Not Specified
Patient Tumor
Histology Pancreatic Moderately Differentiated Ductal Adenocarcinoma
Primary Tissue pancreas
Collection Site pancreas
Tumor Type Primary
Grade Grade 2
Stage pT3N1M0R0 ( Classification: TNM staging system)
PDX model Engraftment
Host Strain Name Site Type Material Material Status Passage
NMRI nude interscapular fat pad heterotopic tissue fragment fresh 0, 1, 2, 3
Model Quality Control
Technique Description Passage
Histology high concordance between xenograft and patient tumour 0,1,2,3
Fingerprinting high concordance between xenograft and patient tumour 0,1,2,3
Collection (Current Model)
Age 46
Diagnosis Pancreatic Moderately Differentiated Ductal Adenocarcinoma
Type Primary
PDX Mouse PAC0016PR
Collection Site pancreas
Sex Female
Race / Ethnicity Not specified / Not Specified
Date Regimen Started Regimen Dose Best Response Duration (Months)
Jan 15 Oxaliplatin and irinotecan and Folinic acid and Fluorouracil Oxaliplatin, 85 mg/m2, levofolic acid, 400 mg/m2, irinotecan, 180 mg/m2, and 5-FU, 400 mg/m2 (bolus), at day 1 and 2400 mg/m2 5-FU continuos infusion on day 1-2. All repeated every 2 weeks / Oxaliplatin, 85 mg/m2, levofolic acid, 400 mg/m2, irinotecan, 180 mg/m2, and 5-FU, 400 mg/m2 (bolus), at day 1 and 2400 mg/m2 5-FU continuos infusion on day 1-2. All repeated every 2 weeks / Oxaliplatin, 85 mg/m2, levofolic acid, 400 mg/m2, irinotecan, 180 mg/m2, and 5-FU, 400 mg/m2 (bolus), at day 1 and 2400 mg/m2 5-FU continuos infusion on day 1-2. All repeated every 2 weeks / Oxaliplatin, 85 mg/m2, levofolic acid, 400 mg/m2, irinotecan, 180 mg/m2, and 5-FU, 400 mg/m2 (bolus), at day 1 and 2400 mg/m2 5-FU continuos infusion on day 1-2. All repeated every 2 weeks Progressive Disease 4.0 / 4.0 / 4.0 / 4.0
May 15 Paclitaxel 80 mg/m2 weekly (3 out of 4) Progressive Disease 4.0
May 14 Folinic acid and Fluorouracil and Oxaliplatin Oxaliplatin, 85 mg/m2, levofolic acid, 400 mg/m2 and 5-FU, 400 mg/m2 (bolus), at day 1 and 2400 mg/m2 5-FU continuos infusion on day 1-2. All repeated every 2 weeks / Oxaliplatin, 85 mg/m2, levofolic acid, 400 mg/m2 and 5-FU, 400 mg/m2 (bolus), at day 1 and 2400 mg/m2 5-FU continuos infusion on day 1-2. All repeated every 2 weeks / Oxaliplatin, 85 mg/m2, levofolic acid, 400 mg/m2 and 5-FU, 400 mg/m2 (bolus), at day 1 and 2400 mg/m2 5-FU continuos infusion on day 1-2. All repeated every 2 weeks Progressive Disease 8.0 / 8.0 / 8.0
Jul 13 Gemcitabine 1000 mg/m2 weekly for 3 wk; every 4 wk for six cycles Stable Disease 7.0

Sample ID:     Histology:     Tumor Type: Engrafted Tumor     Passage:     Platform: